Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2006-02-16
2010-11-23
Mondesi, Robert B (Department: 1645)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C424S130100, C424S143100, C424S141100, C424S152100, C435S007210
Reexamination Certificate
active
07838252
ABSTRACT:
Methods and compositions for treating a subject for an anthrax toxin mediated disease condition are provided. Aspects of the subject methods include administering to a subject an effective amount of an agent that inhibits cellular internalization of an anthrax toxin, e.g., such as a LRP6 modulatory agent. Also provided are active agents suitable for use in the subject methods, as well as pharmaceutical preparations thereof.
REFERENCES:
patent: 6436933 (2002-08-01), Rideout et al.
patent: 7138417 (2006-11-01), Staehle et al.
patent: 7169559 (2007-01-01), Reid et al.
patent: 7282580 (2007-10-01), Singh et al.
patent: 7456264 (2008-11-01), Keler et al.
patent: 2002/0034512 (2002-03-01), Ivins et al.
patent: 2003/0144193 (2003-07-01), Rottman et al.
patent: 2003/0165501 (2003-09-01), DeAlmeida et al.
patent: 2003/0235818 (2003-12-01), Katritch et al.
patent: 2004/0014209 (2004-01-01), Lassar et al.
patent: 2004/0023356 (2004-02-01), Krumlauf et al.
patent: 2004/0038860 (2004-02-01), Allen et al.
patent: 2004/0092454 (2004-05-01), Schadt et al.
patent: 2004/0142877 (2004-07-01), Schadt et al.
patent: 2004/0171559 (2004-09-01), Weissman et al.
patent: 2004/0235166 (2004-11-01), Prockop et al.
patent: 2004/0253249 (2004-12-01), Rudnic et al.
patent: 2004/0258699 (2004-12-01), Bowdish et al.
patent: 2005/0031625 (2005-02-01), Mohamed et al.
patent: 2005/0042634 (2005-02-01), Jones et al.
patent: 2005/0153902 (2005-07-01), Staehle et al.
patent: 2005/0250692 (2005-11-01), Huang
patent: 2005/0261181 (2005-11-01), Wu et al.
patent: 2005/0287149 (2005-12-01), Keler et al.
patent: 2006/0083746 (2006-04-01), Young et al.
patent: 2006/0110801 (2006-05-01), Young et al.
patent: 2006/0148716 (2006-07-01), Jonczyk et al.
patent: 2006/0217298 (2006-09-01), Srivastava
patent: 2006/0257892 (2006-11-01), Cohen et al.
patent: 2006/0258842 (2006-11-01), Groen et al.
patent: 2006/0263791 (2006-11-01), Moon et al.
patent: 2007/0077553 (2007-04-01), Bentwich
patent: 2007/0111253 (2007-05-01), Harada et al.
patent: 2007/0292444 (2007-12-01), Krumlauf et al.
patent: 2008/0020407 (2008-01-01), Jamieson et al.
patent: 2008/0044901 (2008-02-01), Sasai et al.
patent: 2008/0299148 (2008-12-01), Young et al.
patent: 2003/076568 (2003-09-01), None
patent: 2004/053069 (2004-06-01), None
Lacy, D. Borden et al, PNAS, Sep. 7, 2004, vol. 101(36), pp. 13147-13151.
Bann et al, Cell, vol. 124, Mar. 24, 2006, pp. 119-121, LRP6 Holes the Key to the Entry of Anthrax toxin.
Young, John J. e tal, PLoS Pathogens, Mar. 2007, vol. 3(3), e27, pp. 1-9, LRP5 and LRP6 are not required for Protective antigen-mediated Internalization or Lethality of Anthrax Lethal Toxin.
Mourez et al, Nov. 2003, PNAS (USA), vol. 100(24), pp. 13803-138-8, Mapping Dominant Negative mutants of Anthrax Protective Antigen by scanning mutagenesis.
Abrami, L et al, The Journal of Cell Biology, vol. 160(3), pp. 321-328, Feb. 3, 2003, Anthrax toxin triggers endocytosis of its receptor via a lipid raft-mediated clathrin-dependent process.
Wei, W et al 2006, Cell, vol. 124, pp. 1141-1154, Mar. 24, 2006, The LDL Receptor-related protein LRP6 mediates internalization and lethality of Anthrax toxin.
Singh, Y et al, The Journal of Biological Chemistry, vol. 276(25), Jun. 22, 2001, pp. 22090-22094, A Dominant Negative Mutant ofBacillus anthracisProtective antigen inhibits Anthrax toxin action in Vivo.
Young, J.J. et al, PLOS Pathogens, Mar. 2007, vol. 3(3e27), pp. 0001-0009.
Strickland, DK et al, FASEB J., vol. 9, pp. 890-898, 1995, LDL recept0or-related protein: a multiligand receptor for lipoprotein and proteinase catabolism.
Strickland, DK et al, Trends in Endocrinology and Metabolism, vol. 13(2) Mar. 2002, Diverse roles for the LDL receptor family.
Mao, B. et al, Nature, vol. 411, May 17, 2001, LDL receptor related protein 6 is a reeptor for Dickkopf proteins, pp. 321-325.
Davidson, G et al, Development, vol. 129, pp. 5587-5596, 2002.
Itasaki. Nobue et al, Development, vol. 130, pp. 4295-4305, 2003.
Abrami, L et al, J. Cell Biology, vol. 160(3), Feb. 3, 2003, pp. 321-328.
Rainey et al. “Receptor-Specific Requirements for Anthrax Toxin Delivery into Cells,” Proc. Natl. Acad. Sci. (2005) 102(37):13278-13283.
Santelli et al. “Crystal Structureof a Complex Between Anthrax Toxin and its Host Cell Receptor,” Nature (2004) 430(19):905-908.
Scobie et al. “Human Capillary Morphogenesis Protein 2 Functions as an Anthrax Toxin Receptor,” Proc. Natl. Acad. Sci. (2003) 100(9):5170-5174.
Scobie et al. “Interactions Between Anthrax Toxin Receptors and Protective Antigen,” Current Opinion in Microbiology (2005) 8:106-112.
Wei et al. “The LDL Receptor-Related Protein LRP6 Mediates Internalization and Lethality of Anthrax Toxin,” Cell(2006) 124:1141-1154.
Cohen Stanley N.
Wei Wensheng
Bozicevic Field & Francis LLP
Field Bret E.
Mondesi Robert B
Portner Ginny
Scherer David C.
LandOfFree
Methods and compositions for treating a subject having an... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for treating a subject having an..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for treating a subject having an... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4203408